Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. Throughout her career, Ms. Fralick has distinguished herself in a variety of senior roles. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, Ms. Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need, when they need them. Prior to joining Innovative Medicines Canada, Ms. Fralick was President and CEO of the Canadian Cancer Society, Canada’s largest health charity, where she oversaw a three-year process of intense transformation, resulting in historic changes to the operational and governance structures of the organization. Ms. Fralick previously served as president and CEO of the Canadian Healthcare Association (CHA) and as CEO of the Canadian Physiotherapy Association. At both Associations, Ms. Fralick led organizational initiatives designed to enhance sustainability and improve outcomes for the associations, their members and stakeholders. Ms. Fralick has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit. True to her commitment to the health and well-being of Canadians, Ms. Fralick has served on numerous prestigious boards and collaboratives across Canada. She was Chair of the Health Action Lobby (HEAL) and Co-chair the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the board of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair). Ms. Fralick has a BA in French and psychology and an MA in developmental psychology from Carleton University, as well as a Master of Public Administration (MPA) from Queen’s University. She also holds an ICD.D designation. She is trilingual – in English, French and German – and is an accomplished artist and athlete.
Jeremy Slobodan is the Director, Drug Utilization, Information & Stewardship for Alberta Health Services and is based out of Red Deer. His position oversees the AHS drug formulary, drug information and antimicrobial stewardship for Pharmacy Services.
In part, his role includes improving patient care through optimized drug use and working with practitioners to ensure new drugs introduced onto the AHS formulary provide improvements to the health care system.
Jeremy is the Chair of the National Hospital Formulary Collaborative, a member of the Alberta Health Expert Committee on Drug Evaluation & Therapeutics and a past president of the Alberta Pharmacists Association."
Imran Ali is the Senior Manager of the pan-Canadian Pharmaceutical Alliance Office and has been in the role since September 2015. From 2012 to 2015, Imran held the position of Senior Manager with the Agreements & Negotiations Unit in the Ontario Ministry of Health and Long-Term Care’s Negotiations Branch. In this role, Imran provided leadership and direction for planning, priority setting and negotiation of accountability agreements with individual providers and health care organizations to optimize the Ministry’s investment in the health care system valued at over $11 billion annually. Imran provided support for the negotiations process with the Ontario Medical Association (OMA). Prior to this, Imran supported the negotiations of the 2012 Physician Services Agreement with the OMA and lead the coordination of subsequent implementation activities related to the agreement. He also served as the Ministry Co-Chair for the Systems Management Committee, which is responsible for bilateral monitoring and analysis of physician services in Ontario with the OMA. Imran began his career with the Ministry in 2006 with the Primary Health Care Branch where he managed physician services contracts valued in excess of $50 million annually in the Specialized Models Unit. Imran graduated with a Masters in Public Health specializing in Health Policy and Management from the University of Alberta's School of Public Health in 2005.
Ms. Childerhose’s career is focused on optimizing patient outcomes through forming meaningful relationships in the Canadian health care system.
Her career path took her to government early on where she embraced challenges in public relations to improve communications about issues impacting the public in various portfolios, including the Senior’s and Women’s Secretariats, Transportation, Tourism, and Health Care. She was the Communications Lead for the Ministry of Health’s Change Management initiative to change the business model of siloed departments to cross-functional teams, improving communications, optimizing ministry outcomes, and strengthening program accountability.
As the Director for Rx&D (now IMC) in Ontario, Ms. Childerhose led industry initiatives during an especially active time with the goal of advancing industry’s patient-focused value proposition, and economic benefit spin-offs.
Joining Valeant Canada and Bausch + Lomb provided Ms. Childerhose with the opportunity to collaborate directly with the leading Canadian innovative pharmaceutical and medical device organization where she develops and implements strategies to increase the number of innovative products available to Canadians, ensuring business growth and the related health and social benefits for Canadians.
Ms. Childerhose lives in Mississauga with her husband and two daughters.
Christopher Trevors, MS, CGC graduated with a B.Sc. (Honours) in Biology from Queen’s University and a master’s degree in Human Genetics (Genetic Counseling) from Sarah Lawrence College in Bronxville, New York. He worked at the Westchester Medical Center in Hawthorne, New York before starting at The Hospital for Sick Children (SickKids) in Toronto as a genetic counsellor. During his nine years at SickKids he was involved in clinical care before taking on a role as a clinical educator and evaluator in the areas of genetics, ethics and molecular/genomic technologies. Christopher worked as Canadian General Manager of Centogene AG, a German molecular diagnostics company for 3 years before transitioning to help build a genetic diagnostics division at LifeLabs in Toronto as Director of Genetics and Genomics. Christopher is currently the National Director of Genetic Health Solutions at Dynacare and continues to lecture in the University of Toronto Genetic Counselling MSc program, the Medical Laboratory Technology Program at The Michener Institute and the George Brown Nursing Program.
As the National Practice Leader, Drug Benefits Solutions in Great-West Life’s Toronto Group Sales Office, Barbara A. Martinez supports sales offices across Canada on prescription drug management initiatives. She plays a key role in supporting advisors and their clients, including designing and managing drug benefit plans with Great-West Life Drug Solutions programs.
Barbara joined Great-West Life in 2012 after 10 years at Mercer, where she led the Canadian drug benefits consulting team. She’s a regular speaker at industry forums and a frequent commentator on employer drug programs. Her past experience also includes 13 years in the pharmaceutical industry, where she worked in sales and marketing as well as government and professional affairs.